Ann: Immutep Investor Update, page-23

Apologies for jumping in uninvited with my 2 cents worth.

I'm not sure whether to expect an interim trial result for AIPAC, considering the endpoint is expected to be announced in June (or thereabouts).
If that's the likely announcement date, they'd need to begin tabulating patient response data at least a month or so ahead.

As for partnering on AIPAC (IMP321), the only deal currently in place is with Eddingpharm, for the China territory.
That means the rest of the world is not contracted with anyone as yet.

What level of partnering deal is achievable would depend upon the efficacy results from the trial.
That's why I'm excited (and nervous) about the decision not to commit to a deal thus far.

Pick a number and cross your fingers folks.
.